Table 11.
TNFα level (pg/mL) between treatments with: MTX (therapy 1, n = 20), anti-TNFα (therapy 2, n = 20) and anti-IL-17A (therapy 3, n = 10) in patients with plaque psoriasis at three measurement points (week 0, week 4, week 12). * indicates a statistically significant difference (p < 0.05).
| TNFα | Week 0 | Week 4 | Effect (↓) | Week 12 | Effect (↓) |
|---|---|---|---|---|---|
| Therapy 1 | 505.26 ± 223.1 | 329.19 ± 161.8 | 34% | 336.77 ± 103.9 | * 33% |
| Therapy 2 | 722.34 ± 196.1 | 352.92 ± 127.5 | * 51% | 155.07 ± 91.5 | * 78% |
| Therapy 3 | 361.57 ± 75.6 | 342.0 ± 149.0 | 5% | 278.2 ± 76.7 | 23% |